Skip to main content
. 2022 Oct 20;6:e2200261. doi: 10.1200/PO.22.00261

FIG 2.

FIG 2.

Detection of targetable alterations and potential germline variants in liquid biopsies. (A) The percentage of liquid biopsies with clinical reports with in-tumor type therapy associations ranged from 61% of breast cancer specimens to 12% of sarcoma specimens, ordered by cancer type cohort size. The black immunotherapy bar indicates the percentage of samples with detected microsatellite instability (MSI-H) in any tumor type and/or detected bTMB-H in NSCLC and head and neck cancer samples. The percentage of samples with CDx claims on the report are shown in NSCLC, prostate, breast, and ovarian cancer. (B) Focusing on pathogenic variants detected 24 actionable cancer susceptibility genes, and qualifying ClinVar variants detected at > 30% VAF are reported with a banner recommending consideration of germline testing (purple). BER, base excision repair; bTMB-H, high blood tumor mutational burden; CDx, companion diagnostic; HRR, homologous recombination repair; LBx, liquid biopsy; MMR, mismatch repair; MSI-H, high microsatellite instability; NSCLC, non–small-cell lung cancer; VAF, variant allele frequency.